Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Apexigen Adds $65 Million to C Round in Funding Led by China Investors

publication date: Mar 25, 2020

Apexigen, a Bay Area clinical-stage biopharma, closed a $65 million second tranche of its C round that was led by two China investment firms, Decheng and Oceanpine. Last year, Apexigen raised $58 million in the first arm of the C round. Apexigen is developing immunotherapies for oncology, including APX005M, a mAb targeting CD40. Binding of APX005M to CD40 on antigen presenting cells (dendritic cells, monocytes and B-cells) is expected to activate both innate and adaptive immune systems. APX005M is currently being tested in several Phase II trials in multiple solid tumor cancers. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China